The DOI matches its Crossref record; 216 of the 216 references it cites were found in a registry or an index.
Therapeutic application of histone deacetylase inhibitors for central nervous system disorders
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., Roses, A. D., Haines, J. L., & Pericak-Vance, M. A. (1993) · Science · doi:10.1126/science.8346443 · Cited by 9,429
Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2
Amir, R. E., Van den Veyver, I. B., Wan, M., Tran, C. Q., Francke, U., & Zoghbi, H. Y. (1999) · Nature Genetics · doi:10.1038/13810 · Cited by 4,990
Therapeutic potential of resveratrol: the in vivo evidence
Baur, J. A., & Sinclair, D. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2060 · Cited by 3,958
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
Howitz, K. T., Bitterman, K. J., Cohen, H. Y., Lamming, D. W., Lavu, S., Wood, J. G., Zipkin, R. E., Chung, P., Kisielewski, A., Zhang, L.-L., et al. (2003) · Nature · doi:10.1038/nature01960 · Cited by 3,796
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy
Spada, A. R. L., Wilson, E. M., Lubahn, D. B., Harding, A. E., & Fischbeck, K. H. (1991) · Nature · doi:10.1038/352077a0 · Cited by 2,784
Modulation of NF‐κB‐dependent transcription and cell survival by the SIRT1 deacetylase
Yeung, F., Hoberg, J. E., Ramsey, C. S., Keller, M. D., Jones, D. R., Frye, R. A., & Mayo, M. W. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600244 · Cited by 2,750
HDAC6 is a microtubule-associated deacetylase
Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
Research works printed but not linked: 5
- Gallen, C. C. Strategic challenges in neurotherapeutic pharmaceutical development. NeuroRx 1, 165–180 (2004). · doi:10.1602/neurorx.1.1.165
- Thomas, E. A. et al. The histone deacetylase inhibitor, HDACi 4b, ameliorates the disease phenotype and transcriptional abnormalities in Huntington's disease transgenic mice. Proc. Natl Acad. Sci. USA (in the press).
- Mai, A. et al. Synthesis and biological evaluation of 2-, 3-, and 4-acylaminocinnamyl-N-hydroxyamides as novel synthetic HDAC inhibitors. Med. Chem. 1, 245–254 (2005). · doi:10.2174/1573406053765431
- Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409, 581–589 (2008). · DOI · Paper page
- Galletti, P. et al. Diverse effects of natural antioxidants on cyclosporin cytotoxicity in rat renal tubular cells. Nephrol. Dial. Transplant. 20, 1551–1558 (2005). · doi:10.1093/ndt/gfh846
Cited by
Lysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Chemistry and Biology Of Multicomponent Reactions
Dömling, A., Wang, W., & Wang, K. (2012) · Chemical Reviews · doi:10.1021/cr100233r · Cited by 2,547
Suppression of Oxidative Stress by β-Hydroxybutyrate, an Endogenous Histone Deacetylase Inhibitor
Shimazu, T., Hirschey, M. D., Newman, J., He, W., Shirakawa, K., Le Moan, N., Grueter, C. A., Lim, H., Saunders, L. R., Stevens, R. D., et al. (2013) · Science · doi:10.1126/science.1227166 · Cited by 1,777
Genome-wide mapping of HATs and HDACs reveals distinct functions in active and inactive genes
Wang, Z., Zang, C., Cui, K., Schones, D. E., Barski, A., Peng, W., & Zhao, K. (2009) · Cell · doi:10.1016/j.cell.2009.06.049 · Cited by 1,344
“However, the drug development community faces significant challenges in the selection and design of drugs for clinical candidates, partially because of the lack of known targets of HATs and HDACs (Kazantsev and Thompson, 2008).”
BackgroundTargeting bromodomains: epigenetic readers of lysine acetylation
Filippakopoulos, P., & Knapp, S. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4286 · Cited by 1,243
An epigenetic blockade of cognitive functions in the neurodegenerating brain
Gräff, J., Rei, D., Guan, J.-S., Wang, W.-Y., Seo, J., Hennig, K. M., Nieland, T. J. F., Fass, D. M., Kao, P. F., Kahn, M., et al. (2012) · Nature · doi:10.1038/nature10849 · Cited by 853
Molecular Mechanisms and Potential Therapeutical Targets in Huntington's Disease
Zuccato, C., Valenza, M., & Cattaneo, E. (2010) · Physiological Reviews · doi:10.1152/physrev.00041.2009 · Cited by 848
Rational Design and Simple Chemistry Yield a Superior, Neuroprotective HDAC6 Inhibitor, Tubastatin A
Butler, K. V., Kalin, J., Brochier, C., Vistoli, G., Langley, B., & Kozikowski, A. P. (2010) · Journal of the American Chemical Society · doi:10.1021/ja102758v · Cited by 801
Somatic retrotransposition alters the genetic landscape of the human brain
Baillie, J. K., Barnett, M. W., Upton, K. R., Gerhardt, D. J., Richmond, T. A., De Sapio, F., Brennan, P. M., Rizzu, P., Smith, S., Fell, M., et al. (2011) · Nature · doi:10.1038/nature10531 · Cited by 684
“For instance, HDAC1 is a genome-wide transcriptional regulator that controls the canonical L1 promoter 4,25 and is implicated in psychiatric disease and tumorigenesis 26 .”
BackgroundMultiple roles of HDAC inhibition in neurodegenerative conditions
Chuang, D.-M., Leng, Y., Marinova, Z., Kim, H.-J., & Chiu, C.-T. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2009.06.002 · Cited by 676
A short guide to histone deacetylases including recent progress on class II enzymes
Park, S.-Y., & Kim, J.-S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0382-4 · Cited by 509
Epigenetic mechanisms in cognition
Day, J. J., & Sweatt, J. D. (2011) · Neuron · doi:10.1016/j.neuron.2011.05.019 · Cited by 510
The return of the nucleus: transcriptional and epigenetic control of autophagy
Füllgrabe, J., Klionsky, D. J., & Joseph, B. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3716 · Cited by 466
d'Ydewalle, C., Krishnan, J., Chiheb, D. M., Van Damme, P., Irobi, J., Kozikowski, A. P., Berghe, P. V., Timmerman, V., Robberecht, W., & Van Den Bosch, L. (2011) · Nature Medicine · doi:10.1038/nm.2396 · Cited by 454
Targeting the sphingosine-1-phosphate axis in cancer, inflammation and beyond
Kunkel, G. T., Maceyka, M., Milstien, S., & Spiegel, S. (2013) · Nature Reviews Drug Discovery · doi:10.1038/nrd4099 · Cited by 434
Ricobaraza, A., Cuadrado-Tejedor, M., Pérez-Mediavilla, A., Frechilla, D., Del Río, J., & García-Osta, A. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2008.229 · Cited by 423
Release and activity of histone in diseases
Chen, R., Kang, R., Fan, X.-G., & Tang, D. (2014) · Cell Death & Disease · doi:10.1038/cddis.2014.337 · Cited by 419
Targeted Cancer Therapy: Giving Histone Deacetylase Inhibitors All They Need To Succeed
Gryder, B. E., Sodji, Q. H., & Oyelere, A. K. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.3 · Cited by 404
Epigenetic regulation of gene expression in physiological and pathological brain processes
Gräff, J., Kim, D., Dobbin, M. M., & Tsai, L.-H. (2011) · Physiological Reviews · doi:10.1152/physrev.00012.2010 · Cited by 373
The bromodomain interaction module
Filippakopoulos, P., & Knapp, S. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.04.045 · Cited by 374
Reactive Astrocytes As Therapeutic Targets for CNS Disorders
Hamby, M. E., & Sofroniew, M. V. (2010) · Neurotherapeutics · doi:10.1016/j.nurt.2010.07.003 · Cited by 365
Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair
Lee, J.-H., Choy, M. L., Ngo, L., Foster, S. S., & Marks, P. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1008522107 · Cited by 363
Targeting the correct HDAC(s) to treat cognitive disorders
Fischer, A., Sananbenesi, F., Mungenast, A., & Tsai, L.-H. (2010) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2010.09.003 · Cited by 354
The emerging field of epigenetics in neurodegeneration and neuroprotection
Hwang, J.-Y., Aromolaran, K. A., & Zukin, R. S. (2017) · Nature Reviews Neuroscience · doi:10.1038/nrn.2017.46 · Cited by 346
Nicotinamide Improves Aspects of Healthspan, but Not Lifespan, in Mice
Mitchell, S. J., Bernier, M., Aon, M. A., Cortassa, S., Kim, E. Y., Fang, E. F., Palacios, H. H., Ali, A., Navas-Enamorado, I., Di Francesco, A., et al. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.02.001 · Cited by 338
Kataoka, S., Takuma, K., Hara, Y., Maeda, Y., Ago, Y., & Matsuda, T. (2013) · International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001714 · Cited by 341
Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy
Wagner, J. M., Hackanson, B., Lübbert, M., & Jung, M. (2010) · Clinical Epigenetics · doi:10.1007/s13148-010-0012-4 · Cited by 338
The Role of Histone Acetylation in Memory Formation and Cognitive Impairments
Peixoto, L., & Abel, T. (2013) · Neuropsychopharmacology · doi:10.1038/npp.2012.86 · Cited by 338
The Emerging Field of Neuroepigenetics
Sweatt, J. D. (2013) · Neuron · doi:10.1016/j.neuron.2013.10.023 · Cited by 324
HDAC6 is a target for protection and regeneration following injury in the nervous system
Rivieccio, M. A., Brochier, C., Willis, D. E., Walker, B. A., D'Annibale, M. A., McLaughlin, K., Siddiq, A., Kozikowski, A. P., Jaffrey, S. R., Twiss, J. L., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0907935106 · Cited by 322
Drosophila as an In Vivo Model for Human Neurodegenerative Disease
McGurk, L., Berson, A., & Bonini, N. M. (2015) · Genetics · doi:10.1534/genetics.115.179457 · Cited by 318
Inside HDACs with more selective HDAC inhibitors
Roche, J., & Bertrand, P. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.05.047 · Cited by 312
Human Disease-Drug Network Based on Genomic Expression Profiles
Hu, G., & Agarwal, P. (2009) · PLoS ONE · doi:10.1371/journal.pone.0006536 · Cited by 310
Shukla, S., & Tekwani, B. L. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00537 · Cited by 314
Montgomery, R. L., Hsieh, J., Barbosa, A. C., Richardson, J. A., & Olson, E. N. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0902750106 · Cited by 306
The Potential of HDAC Inhibitors as Cognitive Enhancers
Gräff, J., & Tsai, L.-H. (2013) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011112-140216 · Cited by 298
Epigenetic Regulation of the BDNF Gene: Implications for Psychiatric Disorders
Boulle, F., van den Hove, D. L. A., Jakob, S. B., Rutten, B. P., Hamon, M., van Os, J., Lesch, K.-P., Lanfumey, L., Steinbusch, H. W., & Kenis, G. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.107 · Cited by 282
The clinical development of histone deacetylase inhibitors as targeted anticancer drugs
Marks, P. A. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.510514 · Cited by 281
Acetylation site specificities of lysine deacetylase inhibitors in human cells
Schölz, C., Weinert, B. T., Wagner, S. A., Beli, P., Miyake, Y., Qi, J., Jensen, L. J., Streicher, W., McCarthy, A. R., Westwood, N. J., et al. (2015) · Nature Biotechnology · doi:10.1038/nbt.3130 · Cited by 275
Nuclear receptor coregulators: modulators of pathology and therapeutic targets
Lonard, D. M., & O'Malley, B. W. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.100 · Cited by 272
Clinical and Experimental Applications of Sodium Phenylbutyrate
Iannitti, T., & Palmieri, B. (2011) · Drugs in R & D · doi:10.1007/bf03259725 · Cited by 270
Clusterin: A forgotten player in Alzheimer's disease
Nuutinen, T., Suuronen, T., Kauppinen, A., & Salminen, A. (2009) · Brain Research Reviews · doi:10.1016/j.brainresrev.2009.05.007 · Cited by 267
Locus for severity implicates CNS resilience in progression of multiple sclerosis
International Multiple Sclerosis Genetics Consortium, Harroud, A., Stridh, P., McCauley, J. L., Saarela, J., van den Bosch, A. M. R., Engelenburg, H. J., Beecham, A. H., Alfredsson, L., Alikhani, K., et al. (2023) · Nature · doi:10.1038/s41586-023-06250-x · Cited by 285
Zinc binding groups for histone deacetylase inhibitors
Zhang, L., Zhang, J., Jiang, Q., Zhang, L., & Song, W. (2018) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2017.1417274 · Cited by 240
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Millan, M. J. (2013) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.11.015 · Cited by 229
Narita, T., Ito, S., Higashijima, Y., Chu, W. K., Neumann, K., Walter, J., Satpathy, S., Liebner, T., Hamilton, W. B., Maskey, E., et al. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.03.008 · Cited by 228
Epigenetics of stress adaptations in the brain
Stankiewicz, A. M., Swiergiel, A. H., & Lisowski, P. (2013) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2013.07.003 · Cited by 220
Hait, N. C., Wise, L. E., Allegood, J. C., O'Brien, M., Avni, D., Reeves, T. M., Knapp, P. E., Lu, J., Luo, C., Miles, M. F., et al. (2014) · Nature Neuroscience · doi:10.1038/nn.3728 · Cited by 209
Tau – an inhibitor of deacetylase HDAC6 function
Perez, M., Santa‐Maria, I., De Barreda, E. G., Zhu, X., Cuadros, R., Cabrero, J. R., Sanchez‐Madrid, F., Dawson, H. N., Vitek, M. P., Perry, G., et al. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06102.x · Cited by 182
Is there a future for histone deacetylase inhibitors in the pharmacotherapy of psychiatric disorders
Grayson, D. R., Kundakovic, M., & Sharma, R. P. (2010) · Molecular Pharmacology · doi:10.1124/mol.109.061333 · Cited by 171
Melatonin and sirtuins: A “not-so unexpected” relationship
Mayo, J. C., Sainz, R. M., González Menéndez, P., Cepas, V., Tan, D., & Reiter, R. J. (2017) · Journal of Pineal Research · doi:10.1111/jpi.12391 · Cited by 175
Mielcarek, M., Landles, C., Weiss, A., Bradaia, A., Seredenina, T., Inuabasi, L., Osborne, G. F., Wadel, K., Touller, C., Butler, R., et al. (2013) · PLoS Biology · doi:10.1371/journal.pbio.1001717 · Cited by 172
Dichotomous engagement of HDAC3 activity governs inflammatory responses
Nguyen, H. C. B., Adlanmerini, M., Hauck, A. K., & Lazar, M. A. (2020) · Nature · doi:10.1038/s41586-020-2576-2 · Cited by 150
Regulation of Adult Neurogenesis in Mammalian Brain
Niklison-Chirou, M. V., Agostini, M., Amelio, I., & Melino, G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21144869 · Cited by 143
“HDACs are the best-studied histone modifiers in the context of neuronal differentiation [32].”
BackgroundRegulation of chromatin structure in memory formation
Roth, T. L., & Sweatt, J. D. (2009) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2009.05.011 · Cited by 138
Sung, Y. M., Lee, T., Yoon, H., DiBattista, A. M., Song, J. M., Sohn, Y., Moffat, E. I., Turner, R. S., Jung, M., Kim, J., et al. (2013) · Experimental Neurology · doi:10.1016/j.expneurol.2012.10.005 · Cited by 152
Madsen, A. S., & Olsen, C. A. (2012) · Angewandte Chemie International Edition · doi:10.1002/anie.201203754 · Cited by 122
HDAC inhibitors as cognitive enhancers in fear, anxiety and trauma therapy: Where do we stand?
Whittle, N., & Singewald, N. (2014) · Biochemical Society Transactions · doi:10.1042/bst20130233 · Cited by 117
Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition
Kidd, S. K., & Schneider, J. S. (2010) · Brain Research · doi:10.1016/j.brainres.2010.07.041 · Cited by 113
Wu, R., Lu, Z., Cao, Z., & Zhang, Y. (2011) · Journal of the American Chemical Society · doi:10.1021/ja111104p · Cited by 108
Gabriele, M., Lopez Tobon, A., D'Agostino, G., & Testa, G. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.12.013 · Cited by 103
“The first study on human samples showed hypoacetylation of H2A and H2Bin lymphoblastoid cell lines, which could be rescued by HDAC inhibitors (Kazantsev et al., 2008).”
Enhancing autophagy in Alzheimer's disease through drug repositioning
Eshraghi, M., Ahmadi, M., Afshar, S., Lorzadeh, S., Adlimoghaddam, A., Rezvani Jalal, N., West, R., Dastghaib, S., Igder, S., Torshizi, S. R. N., et al. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108171 · Cited by 89
Kaufmann, M., Schuffenhauer, A., Fruh, I., Klein, J., Thiemeyer, A., Rigo, P., Gomez-Mancilla, B., Heidinger-Millot, V., Bouwmeester, T., Schopfer, U., et al. (2015) · SLAS DISCOVERY · doi:10.1177/1087057115588287 · Cited by 87
Targeting Microglial Activation in Stroke Therapy: Pharmacological Tools and Gender Effects
Chen, Y., Won, S. J., Xu, Y., & Swanson, R. A. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666131228203906 · Cited by 81
Cuadrado-Tejedor, M., Garcia-Barroso, C., Sanzhez-Arias, J., Mederos, S., Rabal, O., Ugarte, A., Franco, R., Pascual-Lucas, M., Segura, V., Perea, G., et al. (2015) · Clinical Epigenetics · doi:10.1186/s13148-015-0142-9 · Cited by 69
Botia, B., Legastelois, R., Alaux-Cantin, S., & Naassila, M. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047527 · Cited by 68
Zhang, S., Fujita, Y., Matsuzaki, R., & Yamashita, T. (2018) · Cell Death & Disease · doi:10.1038/s41419-018-0543-8 · Cited by 68
General Base–General Acid Catalysis in Human Histone Deacetylase 8
Gantt, S. M. L., Decroos, C., Lee, M. S., Gullett, L. E., Bowman, C. M., Christianson, D. W., & Fierke, C. A. (2016) · Biochemistry · doi:10.1021/acs.biochem.5b01327 · Cited by 67
The Process and Strategy for Developing Selective Histone Deacetylase 3 Inhibitors
Cao, F., Zwinderman, M., & Dekker, F. (2018) · Molecules · doi:10.3390/molecules23030551 · Cited by 66
A novel small molecule hydroxamate preferentially inhibits HDAC6 activity and tumour growth
Kaliszczak, M., Trousil, S., Åberg, O., Perumal, M., Nguyen, Q.-D., & Aboagye, E. O. (2013) · British Journal of Cancer · doi:10.1038/bjc.2012.576 · Cited by 66
“Histone deacetylase (HDAC) enzymes that affect the acetylation status of histones and various cellular proteins have been recognised as therapeutic targets in central nervous system disorders and cancer (Xu et al, 2007; Kazantsev and Thompson, 2008; Haberland et al, 2009; Marks and Xu, 2009).”
BackgroundKörner, S., Böselt, S., Thau, N., Rath, K. J., Dengler, R., & Petri, S. (2013) · Neurodegenerative Diseases · doi:10.1159/000338048 · Cited by 64
Epigenetic Mechanisms of Rubinstein–Taybi Syndrome
Park, E., Kim, Y., Ryu, H., Kowall, N. W., Lee, J., & Ryu, H. (2014) · NeuroMolecular Medicine · doi:10.1007/s12017-013-8285-3 · Cited by 63
Chen, W.-Y., Zhang, H., Gatta, E., Glover, E. J., Pandey, S. C., & Lasek, A. W. (2019) · Alcohol · doi:10.1016/j.alcohol.2019.02.005 · Cited by 59
Wei, J., Xiong, Z., Lee, J. B., Cheng, J., Duffney, L. J., Matas, E., & Yan, Z. (2016) · The Journal of Neuroscience · doi:10.1523/jneurosci.3056-15.2016 · Cited by 56
Histone deacetylase 6 gates the synaptic action of acute stress in prefrontal cortex
Lee, J. B., Wei, J., Liu, W., Cheng, J., Feng, J., & Yan, Z. (2012) · The Journal of Physiology · doi:10.1113/jphysiol.2011.224907 · Cited by 52
“Indeed, treatment with various HDAC inhibitors has emerged as a promising new strategy for therapeutic intervention in CNS disorders (Kazantsev & Thompson, 2008).”
BackgroundYamada, T., Amann, J. M., Tanimoto, A., Taniguchi, H., Shukuya, T., Timmers, C., Yano, S., Shilo, K., & Carbone, D. P. (2018) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-17-0146 · Cited by 44
Koseki, T., Mouri, A., Mamiya, T., Aoyama, Y., Toriumi, K., Suzuki, S., Nakajima, A., Yamada, T., Nagai, T., & Nabeshima, T. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711001672 · Cited by 44
Fungal KATs/KDACs: A New Highway to Better Antifungal Drugs?
Kuchler, K., Jenull, S., Shivarathri, R., & Chauhan, N. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005938 · Cited by 40
Kitir, B., Maolanon, A. R., Ohm, R. G., Colaço, A. R., Fristrup, P., Madsen, A. S., & Olsen, C. A. (2017) · Biochemistry · doi:10.1021/acs.biochem.7b00725 · Cited by 38
Class I HDAC Inhibitors: Potential New Epigenetic Therapeutics for Alcohol Use Disorder (AUD)
Bourguet, E., Ozdarska, K., Moroy, G., Jeanblanc, J., & Naassila, M. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00115 · Cited by 36
Hirata, Y., Sasaki, T., Kanki, H., Choong, C.-J., Nishiyama, K., Kubo, G., Hotei, A., Taniguchi, M., Mochizuki, H., & Uesato, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-19664-9 · Cited by 20
Medicinal chemistry advances in targeting class I histone deacetylases
Abdallah, D. I., de Araujo, E. D., Patel, N. H., Hasan, L. S., Moriggl, R., Krämer, O. H., & Gunning, P. T. (2023) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2023.00166 · Cited by 17
“Another major drawback to hydroxamates is their poor PKs due to rapid elimination and metabolite cytotoxicity, thus decreasing their potential for clinical use [40].”
BackgroundSimulations suggest pharmacological methods for rescuing long-term potentiation
Smolen, P., Baxter, D. A., & Byrne, J. H. (2014) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2014.07.006 · Cited by 13
Metadata
- Authors
- Kazantsev, A. G., & Thompson, L. M.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2008-10
- Volume
- 7
- Issue
- 10
- Pages
- 854-868
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1996277745
- Cited by
- 711
- References
- 216
- FWCI
- 2.73
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.